Latest / Raleigh News Today | 2 Min News | The Daily News Now!
Eli Lilly’s Pill Breakthrough and Growth Surge | Raleigh News
Eli Lilly’s stock soars past $1,150, fueled by explosive growth in its GLP-1 drugs—Mounjaro and Zepbound—and a major new development: FDA approval for Foundayo, the first pill version of their therapy. This could unlock massive new patient access and extend their growth runway. Q1 results smashed expectations with 56% revenue and 156% EPS growth, plus a bold revenue guidance bump. The real test comes August 5th, when investors will watch for Foundayo adoption, Zepbound supply updates, and whether they’ll raise guidance again. With $750M in U.S. manufacturing expansion, aggressive M&A, and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.